Nebivolol/valsartan combination for the treatment of hypertension: a review
| Autor: | Sarah J Wang, Gary E. Sander |
|---|---|
| Rok vydání: | 2021 |
| Předmět: |
Drug
Angiotensin receptor media_common.quotation_subject Blood Pressure 030204 cardiovascular system & hematology Pharmacology Key issues Nebivolol 03 medical and health sciences 0302 clinical medicine medicine Humans Effective treatment 030212 general & internal medicine Antihypertensive Agents NEBIVOLOL/VALSARTAN media_common business.industry Antagonist Drug Combinations Valsartan Hypertension Molecular Medicine Cardiology and Cardiovascular Medicine business medicine.drug |
| Zdroj: | Future Cardiology. 17:573-583 |
| ISSN: | 1744-8298 1479-6678 |
| DOI: | 10.2217/fca-2020-0079 |
| Popis: | Nebivolol (N) is a β1-adrenoreceptor antagonist that is approved for treatment of hypertension in the USA. Effective treatment of hypertension is becoming an increasingly difficult process that often requires multiple drug combinations to meet target guidelines. This has resulted in the increasing introduction of multidrug single-pill combinations (SPCs) to facilitate cost and compliance issues. Some of the SPCs have added valsartan (V), an angiotensin receptor blocker, which is an increasingly advocated antihypertensive class. Pharmacological profiles of N and V, alone and combined, are well characterized. In 2007, the SPC of N and V, 5 and 80 mg, respectively, was approved by the US FDA for treatment of hypertension. This paper will summarize and update key issues in pharmacology, clinical use and benefit. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|